Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients

Publisher： Karger

E-ISSN： 1423-0399|82|3|249-255

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.82, Iss.3, 2009-05, pp. : 249-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

By  

Current Urology, Vol. 9, Iss. 1, 2015-0 ,pp. : 31-35

Karger

Access to resources Recommend Favorite

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

By  

Urologia Internationalis, Vol. 77, Iss. 2, 2006-08 ,pp. : 135-138

Karger

Access to resources Recommend Favorite

LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion

By de Jong Igle Jan   Eaton Alan   Bladou Franck  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1077-1080

Informa Healthcare

Access to resources Recommend Favorite

New Strategies for Medical Management of Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 80, Iss. 1-2, 2011-05 ,pp. : 1-11

Karger

Access to resources Recommend Favorite

Management of Bone Metastases in Patients with Castration-Resistant Prostate Cancer

By  

Urologia Internationalis, Vol. 92, Iss. 4, 2014-04 ,pp. : 377-386

Karger

Access to resources Recommend Favorite